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Purpose: To investigate the genetic linkage of primary open-angle glaucoma (POAG) in a Chinese family.
Methods: We have screened for myocilin (MYOC) gene mutations in a glaucoma family of five generations. There are
fifty-six members of whom 11 were confirmed to have POAG , two with ocular hypertension were considered as POAG
suspect, and the remaining 43 were asymptomatic. We also recruited 200 unrelated healthy Chinese subjects as normal
control. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis and DNA sequencing
were used to identify mutations in the three exons of MYOC. Presymptomatic diagnoses were made for the family members
seeking consultation based on the results of both clinical examination and genetic analysis.
Results: Among three allelic variants identified in this pedigree (Pro13Leu [38 C→T], Arg76Lys [227G→A], and
Gln337Stop [1009C del]), Pro13Leu and Gln337Stop were reported to be novel mutations while Arg76Lys has been
previously documented. Our results show that all 11 POAG patients carry the Gln337Stop mutation and that four POAG
patients and one POAG suspect (V:2) were found to have the Pro13Leu mutation. In addition, Arg76Lys polymorphism
was identified in two patients and a POAG suspect (V:5).
Conclusions: Pro13Leu and Gln337Stop mutations of MYOC are likely responsible for the etiology of POAG in this
pedigree, but the causative mechanism needs further research.
Glaucoma  is  the  second  leading  cause  of  blindness
worldwide, affecting more than 70 million people. Primary
open-angle glaucoma (POAG) is the most common form of
this ocular disease. A population-based, cross-sectional study
showed that glaucoma is the major cause of blindness in
China, and POAG is a key form of the disease [1]. Noticeably,
incidence  rates  of  secondary  glaucoma  and  congenital
glaucoma are 0.52% and 0.02%, respectively. The prevalence
of primary glaucoma is 1%-2% in the population over age 40.
POAG is usually asymptomatic until the late stage of the
disease. This make early diagnosis almost impossible. And
when POAG reaches the late stage, irreversible damages such
as chronic, progressive apoptosis of optic ganglion cells and
visual field damage usually occur. The most important risk
factor for POAG is family history [2]. First-degree relatives
of individuals affected with POAG are 10 times more likely
to develop POAG [3]. Since its first implication in the genetic
linkage to POAG in 1997, numerous mutations in the myocilin
(MYOC)  gene  have  been  identified  and  their  specific
phenotypes  have  been  characterized.  Although  the
mechanism  underlying  glaucoma  is  poorly  understood,  a
growing body of evidence suggests that there is a genetic link
between MYOC mutations and the pathogenesis of glaucoma.
So  far,  more  than  70  mutations  of  MYOC  have  been
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documented in POAG families or sporadic POAG patients.
Some of them such as Gln48His [4] in exon 1, Asp208Glu
[5] in exon 2, and Pro370Leu [6] and Thr377Met [7] in exon
3  of  MYOC  were  confirmed  to  correlate  with  POAG.
Interestingly, MYOC mutations have been found to vary with
different ethnic groups and geographic locations [8-14]. In the
current study, we performed MYOC mutation screening in a
large glaucoma family affected with POAG, and our results
suggest  that  novel  mutations  of  MYOC,  Pro13Leu  and
Gln337Stop, may be associated with POAG. This study will
also  discuss  the  significance  of  our  findings  to  genetic
counseling.
METHODS
Clinical examination and diagnosis of primary open-angle
glaucoma: Clinical examinations were performed including
visual  acuity,  slit  lamp  biomicroscopy,  applanation
tonometry, gonioscopy, funduscopy, and perimetry. Family
members  were  divided  into  three  groups:  (1)  affected
individuals, (2) asymptomatic individuals, and (3) suspect
individuals. POAG is defined by a normal appearing anterior
chamber angle along with two of the following symptoms
[15]:  elevation  of  intraocular  pressure  (IOP>21  mmHg),
characteristic visual field defects, and glaucomatous optic
nerve head changes (cup-disc ratio>0.6 or notches). Subjects
meeting only one of these symptoms were defined as suspect.
Individuals  without  any  manifestations  were  defined  as
asymptomatic. Patients were diagnosed and treated at the Eye
and ENT Hospital (Fudan University, Shanghai, China). All
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1666participants in this research had given informed consent after
receiving  detailed  explanation  of  the  nature  and  possible
consequences of the study.
Genetic  analysis:  Genomic  DNA  was  extracted  from
peripheral blood leukocytes using standard procedures. The
coding  sequences  of  MYOC  (GenBank  AB006688)  were
amplified  by  polymerase  chain  reaction  (PCR).
Amplifications of three exons were performed in a 25 μl
reaction containing 50 ng of genomic DNA mixed with 10X
buffer,  50  pmol  primers,  2.5  mM  NTP,  and  1  ul  Taq
polymerase.  PCR  conditions  were  as  follows:  initial
denaturation at 94 °C for 5 min followed by 35 cycles of
denaturation at 94 °C for 45 s, annealing at a temperature
specific for each primer for 45 s (Table 1), and extension at
72  °C  for  1  min.  A  final  extension  at  72  °C  for  10  min
TABLE 1. PRIMERS   AND   SEQUENCES   USED   IN THIS STUDY.
ID Position* Tm
(°C)
Sequence (5′→3′) Size (bp)
MYOC1 353–509 62 F: GGCTGGCTCCCC AGTATATA 174
R: ACAGCTGGCATCTCAGGC
MYOC2 491–658 62 F: ACG TTG CTG CAG CTT TGG 196
R: GATGACTGACATGGCCTGG
MYOC3 603–772 65 F: AGTGGCCGATGCCAGTATAC 189
R: CTGGTCCAAGGTCAATTGGT
MYOC4 670–864 62 F: AGGCCATGTCAGTCATCCAT 214
R: TCTCTGGTTTGGGTTTCCAG
MYOC5 778–958 60 F: TGACCTTGGACCAGGCTG 200
R: CCTGGCCAGATTCTCATTTT
MYOC6 928–1095 63 F: TGGAGGAAGAGAAGAAGCGA 187
R: CTGCTGAACTCAGAGTCCCC
MYOC7 1416–1630 62 F: AACATAGTCAATCCTTGGGCC 230
R: TAAAGACCATGTGGGCACA
MYOC8 1933–2091 60 F: TTATGGATTAAGTGGTGCTTCG 177
R: ATTCTCCACGTGGTCTCCTG
MYOC9 2069–2232 64 F: AAGCCCACCTACCCCTACAC 184
R: AATAGAGGCTCCCCGAGTACA
MYOC10 2195–2366 64 F: ATACTGCCTAGGCCACTGGA 190
R: CAATGTCCGTGTAGCCACC
MYOC11 2335–2512 63 F: TGGCTACCACGGACAGTTC 197
R: CATTGGCGACTGACTGCTTA
MYOC12 2480–2653 64 F: GAACTCGAACAAACCTGGGA 195
R: CATGCTGCTGTACTTATAGCGG
MYOC13 2624–2783 62 F: AGCAAGACCCTGACCATCC 179
R: AGCATCTCCTTCTGCCATTG
The  asterisk  indicates  that  all  numbers  correspond  to  the
numbering scheme of GenBank AB006688
completed the reaction. The reactions were performed with a
GeneAmp PCR system 9600 (Applied Biosystems, Foster
City, CA). Subsequently, 8 μl of the PCR product for each
polymorphic site was digested completely with Bme1390 I,
BselI, Eco721, MspI, Bpu11021, PagI, BsmaI, and BseD,
according to instructions recommended by the manufacturer.
Genotype analysis was determined by 12% polyacrylamide
gel.  Direct  sequencing  was  performed  on  an  Applied
Biosystems  3730  DNA  Analyzer  (Applied  Biosystems)
according to the BigDye Terminator version 3.1 protocol.
MYOC mutations were screened in each surviving individual.
Presymptomatic  genetic  diagnoses  were  determined  for
family  members  who  sought  information  and  instruction
about  their  disease  status  according  to  the  phenotype  of
POAG, the pattern of inheritance, their clinical status, and
genetic analysis results of their family. Follow-up plans were
established after these diagnoses.
Secondary  structure  prediction:  We  also  used  Antheprot
software to analyze the possible effects of these mutations on
the secondary structure of the corresponding proteins.
RESULTS
Phenotypes  of  the  patients:  The  five-generation  family
exhibited  an  autosomal  dominant  pattern  of  inheritance
(Figure 1). A total of 11 patients were identified with POAG
(Table 2). The information for III:8, III:14, and III:15 were
not  complete.  Their  diagnoses  were  based  on  medical
histories, which included elevation of intraocular pressure
(IOP >21 mmHg) and characteristic visual field defects.
Onset ages of patients ranged from16 to 41 years. Most
patients had typical glaucoma changes in the optic disc and
the visual field (Figure 2). All patients showed more damage
to the optic nerve head in the right eye than in the left. All
affected  family  members  had  a  noticeable  increase  in
intraocular pressure (IOP) higher than 22 mmHg. The IOP of
these  patients  could  not  be  controlled  with  available
antiglaucoma  medication.  Most  of  the  patients  underwent
Figure 1. Pedigree with variances of MYOC. Solid symbols and open symbols represent affected and unaffected disease status, respectively.
Suspects are marked with a question mark inside the squares. Roman numerals and Arabian numerals indicate generations and orders,
respectively. Squares and circles represent males and females, respectively. A slash indicates a deceased family member. The arrow indicates
the proband.
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1667antiglaucoma  surgeries,  and  subjects  III:1  and  III:8  had
repeated operations due to the failure of the first procedure but
still couldn’t control the development of the pathogenetic
condition.
Clinical examination of the consulters: There were altogether
26 consulters with no visible optic head damage and visual
field defects (Table 3), and two of whom (III:16 and IV:25)
were marked as suspects since their maximum IOP was higher
than 21 mmHg. No evidence for glaucoma was found in the
other 24 consulters.
Mutation screen of MYOC: With polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) and
gene  sequencing  technologies,  we  identified  one  known
mutation,  Arg76Lys  (227G→A),  that  was  reported  as  a
polymorphism by Alward et al. [15], and two novel mutations,
Pro13Leu (38 C→T) and Gln337Stop (1009C del), that are
likely responsible for the pathogenesis of POAG since these
mutations result in either a change in the amino acid sequence
or a frame shift. The three mutations were summarized in
Table 4. The results of PCR-RFLP and gene sequencing are
shown  in  Figure  3.  Other  mutations  i.e.,  Gln48His
(144G→T),  Gly246Arg  (736G→A),  Gln337Arg
(1009C→G),  Ile345Met  (1036  A→G),  Pro370Leu
(1109C→T),  Asp380Asn  (1138G→A),  Asp380Ala
(1139A→C),  Ile477Ser  (1430T→A),  Pro481Thr
(1441C→A), and Pro481Leu (1442C→T), were not detected.
Presymptomatic  diagnosis  for  consulters:  Of  the  26
consulters, two (III:16 and IV: 25) were classified as suspects
because their maximum IOPs were higher than 21 mmHg.
Another two (V:2 and V:10) at high risk for POAG since they
carried the mutation considered to be disease-causing. One
adolescent (V:2) carrying the Arg76Lys (38 C→T) mutation
and another adolescent (V:10) carrying the Gln337Stop (1009
Figure  2.  Optic  disc  and  visual  field  of  individual  IV:22.
Glaucomatous optic disc atrophy is seen with visual field defects in
the right eye. Panel A shows the optic disc atrophy of the right eye
while panel B shows visual field defects of the right eye.
TABLE 2. CLINICAL APPEARANCE OF THE AFFECTED MEMBERS
Family member Sex Age (years) Age of onset
(years)








III:1 M 66 23 OD: NLP 46 ** # End stage Surgery##
OS: NLP 44 ** # End stage Surgery
III:3 F 63 24 OD: NLP * ** # End stage Surgery
OS: NLP * ** # End stage Surgery
III:8 F 56 26 OD: NLP * ** # End stage Surgery##
OS: NLP * ** # End stage Surgery
III:14 F 38 21 OD: NLP * ** # End stage Surgery
OS: NLP * ** # End stage Surgery
III:15 M 35 19 OD: NLP * ** # End stage Surgery
OS: NLP * ** # End stage Surgery
IV:2 F 42 41 OD: 0.5 28 0.7 1 Mild No
OS: 0.4 22 0.6 2 Mild No
IV:4 M 36 26 OD: NLP * ** # End stage Surgery
OS: NLP * ** # End stage Surgery
IV:10 M 30 22 OD:0.01 29 1 8 Severe Surgery
OS: NLP 28 1 # End stage Surgery
IV:14 M 40 16 OD: NLP 29 0.8 # End stage No
OS: NLP 32 0.8 # End stage No
IV:20 M 33 26 OD: NLP 28 ** # End stage No
OS: NLP * ** # End stage Surgery
IV:22 M 35 30 OD: 1.0 18 0.4 0 Mild No
OS: 0.25 35 0.6 3 Moderate No
The asterisk indicates that the maximum intraocular pressure (IOP) was not certain because of relatively advanced glaucoma at
the time of first presentation. The double asterisk indicate that the cup/disc ratio was not certain because of eyeball atrophy or
cornea opacity. The sharp (hash mark) indicates that the visual field was not available because the patient had no light perception.
The double sharp (hash marks) indicates that the member had surgery twice. The visual fields (VF) were graded for severity of
visual field loss with a level grading scale. Severity classification is leveled by the visual field score: mild (0–2), moderate (3–
5), severe (6–8), and end stage (no light perception). NLP, no light perception.
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1668C del) mutation were defined as preclinical status and as
having  a  high  risk  of  developing  glaucoma.  To  prescribe
appropriate  medication  to  carriers  at  an  early  stage  of
glaucoma, follow-up plans were established. The adolescents
were asked to accept applanation tonometry and funduscopy
every month and perimetry every six months.
Prediction  of  two-dimensional  structure:  Protein  analysis
using  Antheprot  suggested  that  Pro13Leu  (38  C→T)  and
Arg76Lys (227 G→A) mutations resulted in the modification
of the corresponding amino acid, but the predicted secondary
structures of the encoded proteins were not different from
those of the wild-types (Table 5). However, the frame shift
introduced by Gln337stop (1009C del) creates a premature
termination codon thereby resulting in a truncated product.
DISCUSSION
MYOC consists of three exons separated by two introns and
encodes a protein of 504 amino acids. Myocilin is a secreted,
55–57 kDa glycoprotein that forms dimers and multimers and
has  several  characteristic  structural  motifs  including  a
myosin-like  domain,  a  leucine  zipper  region,  and  an
olfactomedin  domain  [16].  More  than  70  mutations  in
MYOC have been reported, 90% of which occur within exon
3.  Mutations  in  MYOC  are  found  in  3.86%  of  Caucasian
patients with POAG, including normal tension glaucoma or
ocular hypertension, 3.30% of patients of African descendants
including African Americans and black residents in Africa,
and 4.44% of Asian patients [17].
We have screened a Chinese POAG family for MYOC
base-pair  variants  and  identified  three  allelic  variants,
Pro13Leu (38 C→T), Arg76Lys (227G→A), and Gln337Stop
(1009C del). Since the Arg76Lys mutation in POAG was first
reported in 1998 [15], numerous studies have investigated the
role of MYOC in the etiology of POAG in various ethnic
groups and found that the mutation rate of MYOC ranges from
TABLE 3. CLINICAL FEATURES AND GENE SCREENING RESULTS OF THE CONSULTERS.







III:10 M 54 19 0.3/0.4 0/0 Unaffected
III:12 M 51 20 0.5/0.4 0/0 Unaffected
III:16 F 30 21 0.4/0.4 0/0 Suspect
III:17 M 27 18 0.4/0.3 0/0 Unaffected
IV:6 F 34 17 0.4/0.3 0/0 Unaffected
IV:8 M 32 15 0.3/0.2 0/0 Unaffected
IV:12 M 25 19 0.3/0.3 0/0 Unaffected
IV:16 M 38 20 0.5/0.5 0/0 Unaffected
IV:18 M 36 20 0.5/0.5 0/0 Unaffected
IV:25 M 35 21 0.4/0.3 0/0 Suspect
IV:27 F 30 15 0.4/0.3 0/0 Unaffected
IV:28 M 25 19 0.3/0.3 0/0 Unaffected
IV:29 F 28 16 0.3/0.2 0/0 Unaffected
IV:30 F 24 18 0.4/0.3 0/0 Unaffected
V:1 F 19 18 0.4/0.3 0/0 Unaffected
V:2 M 13 16 0.3/0.5 0/0 Unaffected
V:3 M 11 17 0.4/0.5 0/0 Unaffected
V:4 M 9 16 0.4/0.4 0/0 Unaffected
V:5 M 9 16 0.5/0.5 0/0 Unaffected
V:6 F 16 17 0.4/0.3 0/0 Unaffected
V:7 F 15 18 0.4/0.4 0/0 Unaffected
V:8 F 13 20 0.4/0.3 0/0 Unaffected
V:9 M 10 18 0.4/0.3 0/0 Unaffected
V:10 M 4 20 0.5/0.5 0/0 Unaffected
V:11 F 12 19 0.2/0.4 0/0 Unaffected
V:12 F 8 17 0.3/0.4 0/0 Unaffected
TABLE 4. SUMMARY OF MYOC MUTATIONS FOUND IN THIS STUDY.
Mutation Pedigree members Controls Reference
Arg76Lys (227G→A) 3/56 (5.3%) 0 [15]
Pro13Leu (38 C→T) 5/56 (8.9%) 0 Present study
Gln337Stop (1009C del) 12/56 (21.4%) 0 Present study
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166912% to 18% [18-22]. In contrast to 0% in normal controls, a
mutation  frequency  of  5.3%  (3/56)  in  Arg76Lys  was
identified in the present study, which is lower than previously
reported.  Moreover,  these  mutations  do  not  result  in
significant  alterations  in  either  the  predicted  secondary
structure or the physico-chemical property. Of course, more
samples  should  be  collected  and  analyzed  to  draw  a
conclusion to precisely represent the data generated from the
present study.
Here, we have identified two novel mutations, Pro13Leu
(38C→T) and Gln337stop (1009 C del), in prevalence rates
of 8.9% and 21.4%, respectively, in this family. POAG in one
patient carrying the Pro13Leu mutation eventually developed
into blindness. One subject (IV:25; without the Pro13Leu
mutation) who showed a normal appearance without visible
optic head damage and visual field defects had an IOP of 21
mmHg.  Whether  this  switch  of  amino  acid  residue  has  a
dominant  negative  effect  remains  unknown  and  must  be
Figure  3.  Electrophoretic  mobility
assays  of  PCR-RFLP  and  sequence
results. A: PCR products were separated
on 12% polyacrylamide gel from three
representative  samples,  and  the
genotypes are shown for (1) Arg76Lys
(227G→A), (2) Pro13Leu (38 C→T),
and (3) Gln337Stop (1009C del). The
sizes of the molecular weight marker
and DNA fragments are shown in the
left  and  the  right  sides  of  the  gel,
respectively.  B:  The  representative
chromatogram  contains  the  sequence
from the mutant DNA sequence strand
for (1) Arg76Lys and (2) Pro13Leu as
well as from the (3) wild-type and (4)
mutant DNA sequence of Gln337Stop.
TABLE 5. ANTHEPROT ANALYSIS RESULTS OF THE WILD-TYPE AND MUTANT PROTEIN COMPARISON USING DIFFERENT SECONDARY STRUCTURE
PREDICTION METHODS.







GOR Wild-type 36 23 19 22
Arg76Lys (227G->A) 36 23 19 22
Pro13Leu (38 C->T) 36 23 20 21
Gln337Stop (1009C del) 36 20 20 24
DMP Wild-type 38 28 9 25
Arg76Lys (227G->A) 38 28 9 25
Pro13Leu (38 C->T) 39 28 9 24
Gln337Stop (1009C del) 42 24 10 24
PRD Wild-type 39 13 0 47
Arg76Lys (227G->A) 39 13 0 47
Pro13Leu (38 C->T) 39 13 0 47
Gln337Stop (1009C del) 44 11 0 45
The abbreviations in the “Method” column are; DPM: Double Prediction Method [23], PRD: Predator method [24], GOR:
Garnier, Osguthorpe, Robson [25].
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1670further  studied.  The  other  mutation,  Gln337stop,  was
identified  in  all  clinically  confirmed  patients  and  an
asymptomatic subject V:10 (Gln337stop genotype frequency:
21.4%, 12/56). In this family, Gln337stop was shown to be
one of the most severe and common gene defects that result
in  POAG.  The  present  study  reveals  that  the  Gln337stop
mutation of MYOC is deemed to largely contribute to the early
onset glaucoma in this pedigree. Median onset age of affected
individuals  with  Gln337stop  was  24.9  years.  Nearly  all
patients had to accept surgery due to intraocular pressure. In
addition, the one suspect (V:10) harboring the Gln337stop
mutation was only four years old but had a high IOP and cup-
disc ratio, which made it highly likely to be predisposed to
POAG. Genetically, the loss of cytosine at 1009 creates a
premature stop codon. The resulting truncated product may
have a severe dominant negative effect, which plays a critical
role in etiology of POAG.
Ethnic difference in the frequency and types of MYOC
mutations among patients with POAG has been examined by
case  control  studies.  At  present,  screening  tests  in  whole
populations for MYOC defects are not feasible due to the low
prevalence of MYOC-associated glaucoma. However, people
at high risk of developing glaucoma may benefit from genetic
testing, especially in early onset type of glaucoma pedigrees.
In summary, mutations in MYOC strongly correlate with
the pathogenicity of POAG. Future studies on glaucoma will
be focused on developing an early genetic diagnosis. Such a
test  will  allow  evaluating  the  penetrance  of  MYOC  and
bypassing limitations of the present clinical based methods,
thus providing a chance to prevent the irreversible damages.
ACKNOWLEDGMENTS
We sincerely appreciate the help of the patients, their family
members, and the control subjects for participating in this
study. This work is supported by grants from the National
Natural Science Foundation of China (30672012) and the
Wuhan Municipal Department of Science and Technology
(20016009107) to X.Z. It is also supported by the Hunan
Provincial Natural Science Foundation of China (07JJ6047)
to X.X.
REFERENCES
1. Foster PJ, Oen FT, Machin D, Ng TP, Devereux JG, Johnson
GJ,  Khaw  PT,  Seah  SK.  The  prevalence  of  glaucoma  in
Chinese residents of Singapore: a cross-sectional population
survey of the Tanjing Paper district. Arch Ophthalmol 2000;
118:1105-11. [PMID: 10922206]
2. Fan BJ, Leung YF, Wang N, Lam SC, Liu Y, Tam OS, Pang
CP. Genetic and environmental risk factors for primary open-
angle  glaucoma.  Chin  Med  J  (Engl)  2004;  117:706-10.
[PMID: 15161538]
3. Alward WL. The genetics of open-angle glaucoma: the story of
GLC1A  and  myocilin.  Eye  2000;  14:429-36.  [PMID:
11026970]
4. Mukhopadhyay A, Acharya M, Mukherjee S, Ray J, Choudhury
S, Khan M, Ray K. Mutations in MYOC gene of Indian
primary  open  angle  glaucoma  Patients.  Mol  Vis  2002;
8:442-8. [PMID: 12447164]
5. Lam DS, Leung YF, Chua JK, Baum L, Fan DS, Choy KW,
Pang CP. Truncations in the TIGR gene in individuals with
and  without  primary  open-angle  glaucoma.  Invest
Ophthalmol Vis Sci 2000; 41:1386-91. [PMID: 10798654]
6. Adam  MF,  Belmouden  A,  Binisti  P,  Brézin  AP,  Valtot  F,
Bechetoille A, Dascotte JC, Copin B, Gomez L, Chaventre A,
Bach JF, Garchon HJ. Recurrent mutations in a single exon
encoding  the  evolutionarily  conserved  olfactomedin-
homology domain of TIGR in familial open-angle glaucoma.
Hum Mol Genet 1997; 6:2091-7. [PMID: 9328473]
7. Wiggs JL, Allingham RR, Vollrath D, Jones KH, De La Paz M,
Kern J, Patterson K, Babb VL, Del Bono EA, Broomer BW,
Pericak-Vance MA, Haines JL. Prevalence of mutations in
TIGR/Myocilin in patients with adult and juvenile primary
open-angle glaucoma. Am J Hum Genet 1998; 63:1549-52.
[PMID: 9792882]
8. Jansson M, Marknell T, Tomic L, Larsson LI, Wadelius C.
Allelic variants in the MYOC/TIGR gene in patients with
primary  openangle,  exfoliative  glaucoma  and  unaffected
controls.  Ophthalmic  Genet  2003;  24:103-10.  [PMID:
12789574]
9. Fingert JH, Heon E, Liebmann JM, Yamamoto T, Craig JE, Rait
J, Kawase K, Hoh ST, Buys YM, Dickinson J, Hockey RR,
Williams-Lyn D, Trope G, Kitazawa Y, Ritch R, Mackey DA,
Alward WL, Sheffield VC, Stone EM. Analysis of myocilin
mutations  in  1703  glaucoma  patients  from  five  different
populations.  Hum  Mol  Genet  1999;  8:899-905.  [PMID:
10196380]J.10196380
10. Faucher M, Anctil JL, Rodrigue MA, Duchesne A, Bergeron D,
Blondeau P, Cote G, Dubois S, Bergeron J, Arseneault R,
Morissette  J,  Raymond  V,  Quebec  Glaucoma  Network.
Founder  TIGR/myocilin  mutations  for  glaucoma  in  the
Quebec  population.  Hum  Mol  Genet  2002;  11:2077-90.
[PMID: 12189160]
11. Aldred  MA,  Baumber  L,  Hill  A,  Schwalbe  EC,  Goh  K,
Karwatowski W, Trembath RC. Low prevalence of MYOC
mutations in UK primary open-angle glaucoma patients limits
the utility of genetic testing. Hum Genet 2004; 115:428-31.
[PMID: 15338275]
12. Petersen MB, Kitsos G, Samples JR, Gaudette ND, Economou-
Petersen E, Sykes R, Rust K, Grigoriadou M, Aperis G, Choi
D, Psilas K, Craig JE, Kramer PL, Mackey DA, Wirtz MK.
A  large  GLC1C  Greek  family  with  a  myocilin  T377M
mutation:  inheritance  and  phenotypic  variability.  Invest
Ophthalmol Vis Sci 2006; 47:620-5. [PMID: 16431959]
13. Weisschuh N, Neumann D, Wolf C, Wissinger B, Gramer E.
Prevalence of myocilin and optineurin sequence variants in
German normal tension glaucoma patients. Mol Vis 2005;
11:284-7. [PMID: 15851979]J.15851979
14. Vazquez CM, Herrero OM, Bastus BM, Perez VD. Mutations
in the third exon of the MYOC gene in Spanish patients with
primary  open  angle  glaucoma.  Ophthalmic  Genet  2000;
21:109-15. [PMID: 10916185]
15. Alward WL, Fingert JH, Coote MA, Johnson AT, Lerner SF.
Clinical  features  associated  with  mutations  in  the
chromosome 1 open-angle glaucoma gene (GLC1A). N Engl
J Med 1998; 338:1022-7. [PMID: 9535666]
Molecular Vision 2008; 14:1666-1672 <http://www.molvis.org/molvis/v14/a197> © 2008 Molecular Vision
167116. Gobeil S, Letartre L, Raymond V. Functional analysis of the
glaucoma-causing  TIGR/myocilin  protein:  integrity  of
amino-terminal  coiled-coil  regions  and  olfactomedin
homology domain is essential for extracellular adhesion and
secretion. Exp Eye Res 2006; 82:1017-29. [PMID: 16466712]
17. Gong  G,  Kosoko-Lasaki  O,  Haynatzki  GR,  Wilson  MR.
Genetic dissection of myocilin glaucoma. Hum Mol Genet
2004; 13 Spec No 1:R91-102. [PMID: 14764620]
18. Lam DS, Leung YF, Chua JK, Baum L, Fan DS, Choy KW,
Pang CP. Truncations in the TIGR gene in individuals with
and  without  primary  open-angle  glaucoma.  Invest
Ophthalmol Vis Sci 2000; 41:1386-91. [PMID: 10798654]
19. Pang CP, Leung YF, Fan B, Baum L, Tong WC, Lee WS, Chua
JK, Fan DS, Liu Y, Lam DS. TIGR/MYOC gene sequence
alterations in individuals with and without primary open-
angle  glaucoma.  Invest  Ophthalmol  Vis  Sci  2002;
43:3231-5. [PMID: 12356829]
20. Aroca-Aguilar JD, Sanchez-Sanchez F, Ghosh S, Coca-Prados
M, Escribano J. Myocilin mutations causing glaucoma inhibit
the  intracellular  endoproteolytic  cleavage  of  myocilin
between amino acids Arg226 and Ile227. J Biol Chem 2005;
280:21043-51. [PMID: 15795224]J.15795224
21. Petersen MB, Kitsos G, Samples JR, Gaudette ND, Economou-
Petersen E, Sykes R, Rust K, Grigoriadou M, Aperis G, Choi
D, Psilas K, Craig JE, Kramer PL, Mackey DA, Wirtz MKA.
Large  GLC1C  Greek  family  with  a  myocilin  T377M
mutation:  inheritance  and  phenotypic  variability.  Invest
Ophthalmol Vis Sci 2006; 47:620-5. [PMID: 16431959]
22. Wang DY, Fan BJ, Canlas O, Tam PO, Ritch R, Lam DS, Fan
DS, Pang CP. Absence of myocilin and optineurin mutations
in a large Philippine family with juvenile onset primary open
angle glaucoma. Mol Vis 2004; 10:851-6. [PMID: 15547491]
23. Deléage  G,  Roux  B.  An  algorithm  for  protein  secondary
structure prediction based on class prediction. Protein Eng
1987; 1:289-94. [PMID: 3508279]
24. Frishman D, Argos P. Incorporation of non-local interactions in
protein secondary structure prediction from the amino acid
sequence. Protein Eng 1996; 9:133-42. [PMID: 9005434]
25. Garnier J, Osguthorpe DJ, Robson B. Analysis of the accuracy
and  implications  of  simple  methods  for  predicting  the
secondary structure of globular proteins. J Mol Biol 1978;
120:97-120. [PMID: 642007]
Molecular Vision 2008; 14:1666-1672 <http://www.molvis.org/molvis/v14/a197> © 2008 Molecular Vision
The print version of this article was created on 2 September 2008. This reflects all typographical corrections and errata to the
article through that date. Details of any changes may be found in the online version of the article.
1672